“Efficacy and Safety by Body Weight Decile in Patients Treated With Tildrakizumab 100 Mg for 28 Weeks: Pooled Data Analysis of ReSURFACE 1 and ReSURFACE 2”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s136. https://doi.org/10.25251/skin.7.supp.136.